Eric Pujade-Lauraine, MD, PhD, on Ovarian Cancer: Results From the SOLO2 Trial
2017 ESMO CongressEric Pujade-Lauraine, MD, PhD, of the Université Paris Descartes, discusses phase III study findings on the efficacy of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer by lines of prior chemotherapy (Abstract 932PD).
Related Videos
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combinati...
Judy E. Garber, MD, MPH, on Triple-Negative Breast Cancer: An Update
Judy E. Garber, MD, MPH, of Dana-Farber Cancer Institute, offers expert perspectives on the role of PARP inhibitors in treating triple-negative breast cancer.
Caroline Robert, MD, PhD, on Melanoma: Treatment With Nivolumab and Ipilimumab
Caroline Robert, MD, PhD, of Gustave Roussy, characterizes complete responses in patients with advanced melanoma who received the combination of nivolumab and ipilimumab, or nivolu...
Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial
Andrew R. Clamp, PhD, of The Christie NHS Foundation Trust, discusses his phase III study findings on dose-dense chemotherapy integration in first-line treatment of epithelial ovar...
Karl D. Lewis, MD, on Melanoma: Results From the BRIM8 Trial
Karl D. Lewis, MD, of the Anschutz Cancer Pavilion, discusses study findings on adjuvant vemurafenib in patients with completely resected BRAF V600–positive melanoma at hi...
